Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
- Primary intelligence (targeted KOL and stakeholder interviews to resolve the specific uncertainties in your thesis)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming (via LucidWargames) to stress-test theses and quantify scenario risk
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
February 15, 2026
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL
February 13, 2026
Public Health Video Recap—February 13, 2026
February 13, 2026
Respiratory Today—February 13, 2026
February 13, 2026
Vaccines Today—February 13, 2026
February 13, 2026
Public Health Today—February 13, 2026
February 13, 2026
Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
February 13, 2026
Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH
February 12, 2026
Rare Disease Video Recap—February 12, 2026
February 12, 2026
Cardiovascular Video Recap—February 12, 2026
February 12, 2026